Spero Therapeutics (SPRO) Shares Outstanding (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Shares Outstanding (Entity) came in at $57.9 million in Q1 2026, up 3.56% YoY from $55.9 million in Q1 2025, and up 2.62% on a QoQ basis from $56.4 million in Q4 2025.
Spero Therapeutics (SPRO) Shares Outstanding (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Shares Outstanding (Entity) data on file, last reported at $57.9 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 3.56% year-over-year to $57.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.9 million (up 3.56% YoY) and the FY2025 annual result came in at $56.4 million, up 3.34% from the prior year.
- Shares Outstanding (Entity) climbed to $57.9 million in Q1 2026, from $56.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $57.9 million in Q1 2026 to a low of $32.8 million in Q1 2022.
- A 5-year average of $50.5 million and a median of $53.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) jumped 60.5% — and 2024, when it grew 2.47%.
- Tracing SPRO's Shares Outstanding (Entity) over 5 years: stood at $37.6 million in 2022, then surged by 41.01% to $53.0 million in 2023, then increased by 3.01% to $54.6 million in 2024, then grew by 3.34% to $56.4 million in 2025, then rose by 2.62% to $57.9 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $57.9 million (Q1 2026), $56.4 million (Q4 2025), and $56.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | 57.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.28 Mn |
| Mar 31, 2026 | 57.28 Mn |
| Dec 31, 2025 | 56.02 Mn |
| Sep 30, 2025 | 56.28 Mn |
| Jun 30, 2025 | 56.03 Mn |
| Mar 31, 2025 | 55.38 Mn |
| Dec 31, 2024 | 54.04 Mn |
| Sep 30, 2024 | 54.12 Mn |
| Jun 30, 2024 | 53.96 Mn |
| Mar 31, 2024 | 53.52 Mn |
| Dec 31, 2023 | 52.70 Mn |
| Sep 30, 2023 | 52.71 Mn |
| Jun 30, 2023 | 52.57 Mn |
| Mar 31, 2023 | 52.53 Mn |
| Dec 31, 2022 | 37.59 Mn |
| Sep 30, 2022 | 35.88 Mn |
| Jun 30, 2022 | 32.98 Mn |
| Mar 31, 2022 | 32.61 Mn |
| Dec 31, 2021 | 30.90 Mn |
| Sep 30, 2021 | 32.13 Mn |